Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas

@article{EntinMeer2005ButyricAP,
  title={Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas},
  author={M. Entin-Meer and A. Rephaeli and Xiaodong Yang and A. Nudelman and S. Vandenberg and D. Haas-Kogan},
  journal={Molecular Cancer Therapeutics},
  year={2005},
  volume={4},
  pages={1952 - 1961}
}
Histone modification has emerged as a promising approach to cancer therapy. We explored the efficacy of a novel class of histone deacetylase inhibitors in the treatment of malignant gliomas. Treatment of glioma cell lines with two butyric acid derivatives, pivaloylomethyl butyrate (AN-9) and butyroyloxymethyl butyrate (AN-1), induced hyperacetylation, increased p21Cip1 expression, inhibited proliferation, and enhanced apoptosis. Histone deacetylase inhibitor–induced apoptosis was mediated… Expand
Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)
TLDR
In the sc implanted human colon carcinoma HT-29 xenograft model AN-7, exhibited superior anticancer activity compared to AN-9, as was evident by the significantly greater inhibition of tumor growth and reduction of serum CEA. Expand
Evaluation of the Antitumor and Radiosynthetizing Activity of a Novel Quinoline Sulfonamide Derivative (PIQSA) as a Histone Deacetylase Inhibitor
TLDR
The results suggest that PIQSA exhibited antitumor activities and strong radioenhancing properties associated with inhibition of HDAC activity, DNA fragmentation followed by apoptotic cell death, preferential cell loss of cells particularly in G1/G0 phase through an apoptotic pathway. Expand
In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.
TLDR
The data suggest that AN-9 in combination with radiation may be an effective therapy for malignant gliomas. Expand
Valproic acid induces p21 and topoisomerase-II (α/β) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines
TLDR
This study demonstrates that VPA sensitizes U87, U251, and LN18 cells to the cytotoxic effects of etoposide in vitro by inducing differentiation and up-regulating the expression of p21/WAF1 and both isoforms of topoisomerase-II. Expand
Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors
TLDR
AN446 was the only HDACI tested that exhibited selective HDAC inhibitory activity that was high in cancer cells and low in noncancerous cells, suggesting their effects could be attributed to HDAC inhibition. Expand
The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs
TLDR
In vivo, anti-metastatic activity was evaluated in a metastatic model of lung cancer in which Lewis lung carcinoma cells are injected intravenously into C57/BL mice and produce lung nodules and the good oral bioavailability of AN-7 was confirmed. Expand
Radiosensitization by the Histone Deacetylase Inhibitor PCI-24781
TLDR
PCI-24781 shows promise as a radiosensitizing agent that may compromise the accuracy of repair of radiation damage and inner noncycling cells of SiHa spheroids could be sensitized by nontoxic doses. Expand
A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo.
TLDR
The activities of AN446 (valproyl ester-valpramide of acyclovir) a novel histone deacetylase inhibitor (HDACI) to the previously described AN7 a HDACI prodrug of butyric acid are described and compared. Expand
Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.
TLDR
In vitro and in vivo anti-tumor effect potentiation by abexinostat combined with irradiation in NSCLC is demonstrated and for the first time to the knowledge promising triple combination opportunities with HDACi, irradiation and cisplatin are suggested. Expand
Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination.
TLDR
It is suggested that after a DSB is formed, HDACs deacetylated core histones in the vicinity of the breaks in order to compact the chromatin structure and prevent the broken DNA ends from moving apart from each other, thus ensuring effective repair. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 54 REFERENCES
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
TLDR
The results suggest that hydroxamic acid-based hybrid polar compounds inhibit prostate cancer cell growth and may be useful, relatively nontoxic agents for the treatment of prostate carcinoma. Expand
Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor.
  • J. Kim, J. Shin, I. Kim
  • Medicine
  • International journal of radiation oncology, biology, physics
  • 2004
TLDR
The results suggest that HDAC-Is may be a useful adjunct in the treatment of glioblastoma and merit further investigation, and provide support for clinical trials integrating HDac-I with radiation therapy. Expand
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
TLDR
Results suggest that MS-27-275 acts as an antitumor agent through HDA inhibition and may provide a novel chemotherapeutic strategy for cancers insensitive to traditional antitumors. Expand
Novel anticancer prodrugs of butyric acid. 2.
TLDR
In vivo and in vitro results suggest that (pivaloyloxy)methyl butyrate (1a) is a potential antineoplastic agent. Expand
Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced.
TLDR
Results from in vitro studies indicate that the treatment of human glioma cells with one of the histone deacetylase inhibitors suppresses cell growth with decreasing DNA synthesis and stimulates apoptosis, and that associated molecular mechanisms responsible for these effects include increased histone acetylation as well as enhanced expression of p21 and gelsolin. Expand
In vivo and in vitro antitumor activity of butyroyloxymethyl‐diethyl phosphate (AN‐7), a histone deacetylase inhibitor, in human prostate cancer
TLDR
Since prolonged oral administration with 50 mg/kg or a single oral dose of 1.2 g/kg An‐7 did not cause adverse effects and the former exhibited significant anticancer activity, AN‐7 is likely to display a high therapeutic index and may be beneficial for prostate cancer patients. Expand
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
TLDR
Using xenograft orthotopic models of US, EWS, and neuroblastoma, it is found that the growth of established tumors is inhibited in mice treated with MS-275, and the effects on cell cycle were diverse because in some casesMS-275 induced an increase in G(1) or G(2), whereas in others, there was an induction of apoptosis. Expand
Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells
TLDR
It is demonstrated that AN-9 is a cytostatic but not cytotoxic agent in a myelomonocytic cell line (WEHI); thus, the cells were growth-arrested and differentiated. Expand
Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.
TLDR
HDACIs are potent inhibitors of primary and metastatic UM cell growth and induction of apoptosis in all melanoma cell lines in a concentration-dependent manner in vitro, and these data support further clinical evaluation of depsipeptide and other HDACIs in patients with primary and cancerous uveal melanoma. Expand
Enhancement of Radiation Sensitivity of Human Squamous Carcinoma Cells by Histone Deacetylase Inhibitors
TLDR
Results implicate G1 arrest and inhibition of DNA synthesis in the mechanisms underlying radiation sensitization by trichostatin A and support the use of HDAC inhibitors for targeting radioresistant cancers. Expand
...
1
2
3
4
5
...